167 related articles for article (PubMed ID: 12509279)
1. A novel p53 mutant retained functional activity in lung carcinomas.
Ko JL; Chiao MC; Chang SL; Lin P; Lin JC; Sheu GT; Lee H
DNA Repair (Amst); 2002 Sep; 1(9):755-62. PubMed ID: 12509279
[TBL] [Abstract][Full Text] [Related]
2. Modulation of wild-type p53 activity by mutant p53 R273H depends on the p53 responsive element (p53RE). A comparative study between the p53REs of the MDM2, WAFI/Cip1 and Bax genes in the lung cancer environment. WAFI/Cip1 = WAF1/Cip1.
Zacharatos PV; Gorgoulis VG; Kotsinas A; Manolis EN; Liloglou T; Rassidakis AN; Kanavaros P; Field JD; Halazonetis T; Kittas C
Anticancer Res; 1999; 19(1A):579-87. PubMed ID: 10226602
[TBL] [Abstract][Full Text] [Related]
3. Mdm2 inhibition of p53 induces E2F1 transactivation via p21.
Wunderlich M; Berberich SJ
Oncogene; 2002 Jun; 21(28):4414-21. PubMed ID: 12080472
[TBL] [Abstract][Full Text] [Related]
4. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
5. p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines.
Aurelio ON; Kong XT; Gupta S; Stanbridge EJ
Mol Cell Biol; 2000 Feb; 20(3):770-8. PubMed ID: 10629033
[TBL] [Abstract][Full Text] [Related]
6. Definition of a p53 transactivation function-deficient mutant and characterization of two independent p53 transactivation subdomains.
Venot C; Maratrat M; Sierra V; Conseiller E; Debussche L
Oncogene; 1999 Apr; 18(14):2405-10. PubMed ID: 10327062
[TBL] [Abstract][Full Text] [Related]
7. Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs).
Gorgoulis VG; Zacharatos P; Kotsinas A; Mariatos G; Liloglou T; Vogiatzi T; Foukas P; Rassidakis G; Garinis G; Ioannides T; Zoumpourlis V; Bramis J; Michail PO; Asimacopoulos PJ; Field JK; Kittas C
Mol Med; 2000 Mar; 6(3):208-37. PubMed ID: 10965496
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function.
Kong XT; Gao H; Stanbridge EJ
J Biol Chem; 2001 Aug; 276(35):32990-3000. PubMed ID: 11395510
[TBL] [Abstract][Full Text] [Related]
9. The HAUSP gene plays an important role in non-small cell lung carcinogenesis through p53-dependent pathways.
Masuya D; Huang C; Liu D; Nakashima T; Yokomise H; Ueno M; Nakashima N; Sumitomo S
J Pathol; 2006 Apr; 208(5):724-32. PubMed ID: 16450335
[TBL] [Abstract][Full Text] [Related]
10. Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143.
Li Y; Raffo AJ; Drew L; Mao Y; Tran A; Petrylak DP; Fine RL
Cancer Res; 2003 Apr; 63(7):1527-33. PubMed ID: 12670900
[TBL] [Abstract][Full Text] [Related]
11. Growth suppression by a p14(ARF) exon 1beta adenovirus in human tumor cell lines of varying p53 and Rb status.
Saadatmandi N; Tyler T; Huang Y; Haghighi A; Frost G; Borgstrom P; Gjerset RA
Cancer Gene Ther; 2002 Oct; 9(10):830-9. PubMed ID: 12224024
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions.
Blagosklonny MV; Giannakakou P; Romanova LY; Ryan KM; Vousden KH; Fojo T
Carcinogenesis; 2001 Jun; 22(6):861-7. PubMed ID: 11375890
[TBL] [Abstract][Full Text] [Related]
13. HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter.
Stros M; Ozaki T; Bacikova A; Kageyama H; Nakagawara A
J Biol Chem; 2002 Mar; 277(9):7157-64. PubMed ID: 11748232
[TBL] [Abstract][Full Text] [Related]
14. Ets1 is required for p53 transcriptional activity in UV-induced apoptosis in embryonic stem cells.
Xu D; Wilson TJ; Chan D; De Luca E; Zhou J; Hertzog PJ; Kola I
EMBO J; 2002 Aug; 21(15):4081-93. PubMed ID: 12145208
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53.
Shinagawa Y; Kawamata H; Omotehara F; Nakashiro K; Hoque MO; Furihata T; Horiuchi H; Imai Y; Fujimori T; Fujibayashi T
Int J Oncol; 2003 Feb; 22(2):383-9. PubMed ID: 12527938
[TBL] [Abstract][Full Text] [Related]
16. MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer.
Ko JL; Cheng YW; Chang SL; Su JM; Chen CY; Lee H
Int J Cancer; 2000 May; 89(3):265-70. PubMed ID: 10861503
[TBL] [Abstract][Full Text] [Related]
17. Implication of p53 in growth arrest and apoptosis induced by the synthetic retinoid CD437 in human lung cancer cells.
Sun SY; Yue P; Wu GS; El-Deiry WS; Shroot B; Hong WK; Lotan R
Cancer Res; 1999 Jun; 59(12):2829-33. PubMed ID: 10383141
[TBL] [Abstract][Full Text] [Related]
18. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding.
Wang W; Takimoto R; Rastinejad F; El-Deiry WS
Mol Cell Biol; 2003 Mar; 23(6):2171-81. PubMed ID: 12612087
[TBL] [Abstract][Full Text] [Related]
19. Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene.
Gorgoulis VG; Zacharatos PV; Manolis E; Ikonomopoulos JA; Damalas A; Lamprinopoulos C; Rassidakis GZ; Zoumpourlis V; Kotsinas A; Rassidakis AN; Halazonetis TD; Kittas C
Br J Cancer; 1998; 77(3):374-84. PubMed ID: 9472631
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
